Preliminary results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee using ActiPatch Therapy have been announced.
BioElectronics Corporation says the initial interim analysis showed statistically significant results for the primary and secondary outcomes measures. The study is being led by Doctor Gianluca Bagnato, Division of Rheumatology, University Hospital Gaetano Martino, Messina, Italy. The final analysis of the full study data set will be carried out soon and the results have been accepted in the Annals of the Rheumatic Diseases and presented at the European League against Rheumatism 2014 conference.
"The completion of these randomized, placebo controlled trials, on pain resulting from three very distinct musculoskeletal pathophysiological processes, is highly significant," commented Andrew Whelan, BioElectronics CEO. "The data from these high quality clinical trials will be available before the FDA's May 21st deadline for comments on proposed reclassification of our devices to Class II. This schedule will allow us to submit the 510K application without any delay once the final ruling is made by the FDA."
BioElectronics is conducting a series of clinical research studies using its medical devices for other musculoskeletal pain conditions that include, acute nonspecific lower back pain, as well as the surgical indications of postoperative recovery for 3rd molar extraction and hernia repair.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- M60-UCD1: Tiny Galaxy, Supermassive Black Hole
- Longer Telomeres And Genetic Determinant For Melanoma Risk
- Life After The 125 GeV Higgs: What Is Left Of Two-Higgs Doublet Models
- Ig Nobel Prizes 2014: From Jesus On Toast To Baby Feces In Sausages
- UM171: New Molecule Allows For 10X Increase In Adult Stem Cell Transplants
- Watching Neurons Learn: Learning New Ideas Is More Difficult
- Launching America to Space: Enthusiastic Reception for NASA's Commercial Crew Decision
- "Right on, and I have written articles on that issue in the past - by preventing uptake in wealthy..."
- "Genetic algorithms would be a step back toward (simulation of) evolution in isolated testbeds (computer)..."
- "That's all true. However, if you're in a country where a weeks wages amounts to say $20,..."
- "That is not a greed issue, as is commonly portrayed, it is a 'herd immunity' issue. Just like overuse..."
- "The one problem with some of the GM foods isn't the genetics or the modifications...it's that patents..."